Acomplia
rimonabant
Table of contents
Overview
The marketing authorisation for Acomplia has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Acomplia
|
| Agency product number |
EMEA/H/C/000666
|
| Active substance |
rimonabant
|
| International non-proprietary name (INN) or common name |
rimonabant
|
| Therapeutic area (MeSH) |
Obesity
|
| Anatomical therapeutic chemical (ATC) code |
A08AX01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
sanofi-aventis
|
| Revision |
8
|
| Date of issue of marketing authorisation valid throughout the European Union |
19/06/2006
|
| Contact address |
74, avenue de France
F - 75013 Paris France |
Product information
17/07/2008 Acomplia - EMEA/H/C/000666 - II/0011
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiobesity preparations, excl. diet products
Therapeutic indication
As an adjunct to diet and exercise for the treatment of obese patients (BMI 30 kg/m2), or overweight patients (BMI 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).